Income Statement
Revenue$3.0B
Gross Profit$2.6B
Operating Income$1.1B
EBITDA$1.2B
Net Income$1.0B
VRTX
Vertex Pharmaceuticals Incorporated
NMSSector: HealthcareIndustry: Biotechnology
Valuation
Market Cap
$122.63B
Enterprise Value
$115.35B
P/E
28.6
TTMFwd P/E
22.5
1YP/B
6.3
P/S
10.0
TTMPEG
1.79
EV/EBITDA
23.2
EV/Revenue
9.4
FCF Yield
3.5%
EPS (TTM)
$16.87
Fwd EPS
$21.47
Book Value
$76.18
Market Data
Beta
0.31
Avg Volume
1.3M
Shares Out
253.8M
Float
253.0M
Short % Float
2.0%
Insider %
0.2%
Institutional %
98.0%
D/E
10.3
Current Ratio
3.0
ROE
24.2%
ROA
12.1%
Rev Growth
7.8%
Net Inc Growth
61.4%
Profit Margin
35.5%
Op Margin
38.1%
Gross Margin
54.4%
Total Cash
$7.25B
Total Debt
$1.99B
Financials
Latest period financial summary
Balance Sheet
Total Assets$26.5B
Current Assets$11.7B
Cash$5.5B
Total Liabilities$7.1B
Equity$19.4B
Total Debt$2.0B
Cash Flow
Operating CF$1.4B
Investing CF$-431.9M
Financing CF$-538.8M
Free Cash Flow$1.3B
Financial Trends
Revenue$3.0B
2022/122026/3
Net Income$1.0B
2022/122026/3
EBITDA$1.2B
2022/122026/3
Free Cash Flow$1.3B
2022/122026/3
Period Analysis
Margins & Ratios
| Metric | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/3 | 2025/6 | 2025/9 | 2025/12 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $8.9B | $9.9B | $11.0B | $2.8B | $3.0B | $3.1B | $12.0B |
| Gross Margin | — | +87.9% | +87.2% | +86.1% | +86.9% | +86.3% | +86.5% | +86.2% |
| EBITDA Margin | — | +49.0% | +46.1% | +4.4% | +53.4% | +45.2% | +45.8% | +43.7% |
| Operating Margin | — | +47.6% | +38.3% | -2.1% | +37.2% | +38.9% | +40.3% | +37.9% |
| Net Margin | — | +37.2% | +36.7% | -4.9% | +23.3% | +34.8% | +35.2% | +32.9% |
| Current Ratio | — | 4.83 | 3.99 | 2.69 | 2.65 | 2.52 | 2.36 | 2.90 |
| Debt / Equity | — | 0.06 | 0.05 | 0.11 | 0.10 | 0.09 | 0.11 | 0.11 |
| Net Debt / EBITDA | — | -2.19 | -2.10 | -5.82 | -2.04 | -2.57 | -2.20 | -0.58 |
| ROE | — | +23.9% | +20.6% | -3.3% | +3.9% | +6.0% | +6.3% | +21.2% |
| ROA | — | +18.3% | +15.9% | -2.4% | +2.8% | +4.3% | +4.4% | +15.4% |
| Leverage | — | 0.23 | 0.23 | 0.27 | 0.28 | 0.29 | 0.30 | 0.27 |
Company Profile
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Employees
6K
Location
Boston, MA
Country
US
Golden Bazaar VerifiedUpdated: Jun 25, 2026Data Source: Golden Bazaar Verified · Updated: Jun 25, 2026
Sector Peers
Comparison Screen →Healthcare
Compare with similar companies in the same sector.
This page is prepared by Golden Bazaar using publicly available data. Not investment advice.